Handelsbanken Fonder AB Has $661,000 Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Handelsbanken Fonder AB grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 7.5% in the fourth quarter, HoldingsChannel reports. The fund owned 21,600 shares of the biotechnology company’s stock after acquiring an additional 1,500 shares during the period. Handelsbanken Fonder AB’s holdings in Arrowhead Pharmaceuticals were worth $661,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ARWR. Washington Trust Advisors Inc. acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter worth $25,000. Fifth Third Bancorp boosted its stake in shares of Arrowhead Pharmaceuticals by 112.0% during the 3rd quarter. Fifth Third Bancorp now owns 988 shares of the biotechnology company’s stock worth $27,000 after buying an additional 522 shares during the last quarter. Friedenthal Financial bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $51,000. China Universal Asset Management Co. Ltd. increased its position in shares of Arrowhead Pharmaceuticals by 96.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,753 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 1,352 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 130.1% during the third quarter. Nisa Investment Advisors LLC now owns 5,270 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 2,980 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu bought 1,000 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were purchased at an average price of $27.49 per share, for a total transaction of $27,490.00. Following the transaction, the director now directly owns 31,680 shares in the company, valued at approximately $870,883.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 57,499 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $32.35, for a total value of $1,860,092.65. Following the completion of the transaction, the chief executive officer now directly owns 3,715,048 shares of the company’s stock, valued at approximately $120,181,802.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hongbo Lu bought 1,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, March 18th. The shares were bought at an average cost of $27.49 per share, for a total transaction of $27,490.00. Following the completion of the acquisition, the director now owns 31,680 shares in the company, valued at approximately $870,883.20. The disclosure for this purchase can be found here. Corporate insiders own 4.50% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 4.6 %

Shares of NASDAQ:ARWR opened at $23.13 on Tuesday. The stock has a market cap of $2.87 billion, a PE ratio of -8.32 and a beta of 0.71. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $20.67 and a 12-month high of $42.48. The business has a 50 day moving average of $27.85 and a 200-day moving average of $28.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.46). The firm had revenue of $3.55 million during the quarter, compared to analyst estimates of $35.60 million. Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 90.77%. The business’s quarterly revenue was down 94.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.39) earnings per share. Equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ARWR. Royal Bank of Canada restated an “outperform” rating and issued a $50.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. Citigroup boosted their target price on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the stock a “neutral” rating in a report on Wednesday, February 7th. Morgan Stanley upped their price target on shares of Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Bank of America lifted their price objective on shares of Arrowhead Pharmaceuticals from $29.00 to $37.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.80.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.